Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of a K+ Channel Agonist, XEN1101, For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis.

Muscle & nerve - 1 Apr 2026

Chanchykov Viktor, Iype Sharon, Quinonez Marbella, Wu Fenfen, Cannon Stephen

Abstract excerpt

INTRODUCTION/AIMS: Effective management remains lacking for recurrent episodes of acute weakness in hypokalemic periodic paralysis (HypoPP). We assessed the efficacy of a second-generation potassium channel agonist, XEN1101, to prevent and abort the low-K+ induced loss of force in mouse models of HypoPP. METHODS: An ex vivo contractility assay was used to interrogate the efficacy of XEN1101 for preserving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcium Channels, L-Type
Share to Hypokalemic Periodic Paralysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Transgenic

Share to Muscle Contraction

Share to Muscle, Skeletal

Share to NAV1.4 Voltage-Gated Sodium Channel

Share to Potassium

Share to Potassium Channels

Source

Open in PubMed Open full text

Identifiers

PMID: 41562289
DOI: 10.1002/mus.70159
PMCID: PMC12969960

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of a K+ Channel Agonist, XEN1101, For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis.PMID 41562289Read ↗

Efficacy of Retigabine in Treating Weakness in a Mouse Model of Hypokalemic Periodic Paralysis.Semantic proximity Read ↗

A sodium channel knockin mutant (NaV1.4-R669H) mouse model of hypokalemic periodic paralysis.Semantic proximity Read ↗

A calcium channel mutant mouse model of hypokalemic periodic paralysis.Semantic proximity Read ↗

Voltage-Dependent Ca <sup>2+</sup> Release Is Impaired in Hypokalemic Periodic Paralysis Caused by Ca <sub>V</sub> 1.1-R528H but not by Na <sub>V</sub> 1.4-R669HSemantic proximity Read ↗

The primary periodic paralyses: diagnosis, pathogenesis and treatment.Semantic proximity Read ↗

Contractile abnormalities of mouse muscles expressing hyperkalemic periodic paralysis mutant NaV1.4 channels do not correlate with Na+ influx or channel content.Semantic proximity Read ↗

Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis.Semantic proximity Read ↗

Semaglutide Reverses the Chronic Myopathy of Hyperkalemic Periodic Paralysis: A Case ReportSemantic proximity Read ↗

Targeted mutation of mouse skeletal muscle sodium channel produces myotonia and potassium-sensitive weakness.Semantic proximity Read ↗

Hypokalemic periodic paralysis: an autosomal dominant muscle disorder caused by mutations in a voltage-gated calcium channel.Semantic proximity Read ↗

Sinus arrest in familial hypokalemic periodic paralysis caused by SCN4A mutation: a case report.Semantic proximity Read ↗

Muscle channelopathies: the nondystrophic myotonias and periodic paralyses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.